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ABSTRACT
Background: The pretreatment neutrophil-to-lymphocyte ratio has prognostic 
value after radical prostatectomy for treating localized prostate cancer. However, 
the use of postoperative neutrophil-to-lymphocyte ratio has not been evaluated in 
this population. We investigated the prognostic significance of early postoperative 
neutrophil-to-lymphocyte ratio after radical prostatectomy for prostate cancer.
Methods: We retrospectively reviewed clinical data from 2,302 patients with 
localized prostate cancer who underwent radical prostatectomy at our institution 
between years 2000 and 2010. Only patients with pre- and postoperative complete 
blood counts with differential results were included. Patients who received 
neoadjuvant or postoperative adjuvant treatment and those without adequate medical 
records were excluded. Kaplan-Meier analyses were performed to analyze biochemical 
recurrence-free survival and overall survival rates. Univariate and multivariate Cox 
regression models were used for each endpoint.
Results: Kaplan-Meier curves showed that high postoperative neutrophil-to-
lymphocyte ratio (>3.5) was significantly associated with decreased biochemical 
recurrence-free survival (p = 0.009) and overall survival (p = 0.010). In the 
univariate and multivariate Cox regression analyses, high postoperative neutrophil-
to-lymphocyte ratio was a significant predictor of biochemical recurrence (hazard 
ratio 1.270, p = 0.008) and overall survival (hazard ratio 1.437, p = 0.033).
Conclusions: Our results demonstrate that postoperative neutrophil-to-
lymphocyte ratio is an independent factor for biochemical recurrence and overall 
survival in patients who underwent radical prostatectomy for prostate cancer. These 
findings suggest that neutrophil-to-lymphocyte ratio can be a potentially valuable tool 
for stratifying high-risk patients and facilitating choices of postoperative therapy in 
patients with prostate cancer.
INTRODUCTION
Virchow first proposed a connection between 
inflammation and cancer in 1876, and findings since 
then suggest that the host inflammatory response plays 
an important role in cancer development and progression 
[1–3]. In particular, the systemic inflammatory response, 
as evidenced by surrogate blood-based parameters such 
as C-reactive protein or circulating inflammatory blood 
cells, plays crucial parts in the recurrence, progression, 
metastasis, and survival of cancer cells in a variety of 
malignancies [4–6]. Several studies published in the 
last decade have shown that an increased neutrophil-
to-lymphocyte ratio (NLR) has prognostic value in 
patients with localized and advanced cancers including 
gastrointestinal, liver, lung, breast, ovaries, and 
urological cancers [4, 5, 7–12].
In the case of prostate cancer (PC), many studies 
have shown that NLR has prognostic value in patients 
with metastatic castration-resistant PC receiving 
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chemotherapy [13–15]. A few studies reported that 
an elevated NLR has prognostic value after radical 
prostatectomy (RP) for localized PC [16–18]. However, 
most of these focused on the prognostic value of NLR 
in the preoperative setting; no study has assessed the 
association between postoperative NLR and prognosis 
after RP for PC. According to some reports [12, 19, 20], 
the NLR after potentially curative tumor resection can 
better reflect a patient’s systemic immune responses, 
which could influence cancer prognosis.
Here we tested the hypothesis that postoperative 
NLR can predict oncologic outcome after RP for PC. 
We examined clinical and pathological characteristics 
according to postoperative NLR during the recovery 
period to evaluate the influence of postoperative NLR on 
biochemical recurrence (BCR)-free survival and overall 
survival (OS) in patients following RP for PC.
RESULTS
Descriptive statistics
A total of 2,032 PC patients were included. The 
median follow-up from RP was 78 months (interquartile 
range [IQR] 65–95), and the median postoperative 
NLR was 2.3 (IQR 1.6–3.5). The median time from RP 
to determination of postoperative NLR was 78 days 
(IQR 68−84). Table 1 shows the patients’ clinical and 
pathological features, which are stratified into groups by 
postoperative NLR (high > 3.5 and low ≤ 3.5). We found 
significant differences in age, preoperative prostate-
specific antigen (PSA) level, body mass index (BMI), and 
pathological stage between the groups. Patients in the high 
NLR group had higher neutrophil and lower lymphocyte 
counts. Meanwhile, we found no significant differences 
in hypertension, diabetes mellitus (DM), cardiovascular 
disease (CVD), and prior cerebral vascular accident (CVA) 
between the groups.
Postoperative NLR and biochemical recurrence
In all, 665 (32.7%) men had experienced BCR. 
There were 495 (31.3%) and 170 (37.5%) patients with 
BCR in low and high NLR groups, respectively. The 
5-year BCR-free survival rates were 67.4% and 62.4%, 
while the 10-year BCR-free survival rates were 62.9% and 
57.2% in low and high NLR groups, respectively. Kaplan-
Meier curves showed that the BCR-free survival rate for 
men with high NLR was worse compared to men with low 
NLR (log-rank test; p = 0.009, Figure 1).
In both univariate and multivariate Cox regression 
analyses, patient’s age (hazard ratio [HR] 1.012, p 
= 0.040), preoperative PSA (HR 1.004, p < 0.001), 
Gleason score (HR 3.069, p <0.001), positive surgical 
margin (PSM; HR 1.992, p < 0.001), T-stage (HR 1.469, 
p < 0.001), lymph node (LN) metastasis (HR 1.535, 
p = 0.002), and NLR (HR 1.270, p = 0.008) were all 
independent prognostic factors for BCR (Table 2).
Postoperative NLR and overall survival
In the current study, 160 (7.9%) men died during 
follow-up due to all possible causes. Of these deaths, 
103 (6.5%) patients were from the low NLR group and 
57 (12.6%) were from the high NLR group. The 5-year 
OS rates of the low and high NLR groups were 95.4% 
and 92.5%, while the 10-year OS rates were 89.3% and 
85.4%, respectively. Kaplan-Meier curves showed that OS 
for men with high NLR was worse than those with low 
NLR (log-rank test; p = 0.010, Figure 2).
In our univariate and multivariate Cox regression 
analyses, patient’s age (HR 1.079, p < 0.001), DM (HR 
1.476, p = 0.033), Gleason score (HR 1.643, p = 0.014), 
LN metastasis (HR 2.336, p < 0.001), and NLR (HR 
1.437, p = 0.033) were all independent prognostic factors 
for OS (Table 3).
DISCUSSION
Several studies suggested that a systemic 
inflammatory response is associated with a poor oncologic 
outcome in multiple cancers [4–6]. NLR is a widely used 
systemic inflammatory marker because of its low cost 
and wide availability in clinical practice. Although the 
exact mechanism underlying the poor prognostic impact 
of an elevated NLR remains unclear, this association may 
relate to increased neutrophil-dependent inflammation and 
a decreased lymphocyte-mediated tumor response [21]. 
Malignant tumor cells secrete a variety of pro-inflammatory 
cytokines and negative modulators of anti-tumor immunity 
that may cause relative neutrophilia and lymphocytopenia. 
Neutrophils contribute to enhanced angiogenesis and 
tumor cell intravasation [22]. In addition, circulating 
neutrophils produce inflammatory mediators such as tumor 
necrosis factor and interleukin, which promote tumor cell 
proliferation and angiogenesis [23]. Lymphocytes are 
involved in cytotoxic cell death and cytokine production, 
which inhibits tumor cell proliferation and metastasis [24]. 
The presence of lymphocytes in a tumor is associated with 
better responses to cytotoxic treatment and a more favorable 
prognosis among cancer patients [25].
NLR was previously shown to predict metastatic 
castration-resistant PC survival [13–15]. Several recent 
studies suggested that elevated NLR can be an independent 
prognostic factor for oncological outcomes in localized PC 
[16-18, 22]. Although there were a few studies dealing 
with relationship between NLR and BCR after RP, the 
reported cut-off values were inconsistent [16-18, 26, 
27]. Minardi et al. reported that patients with high NLRs 
had a greater incidence of BCR [18]. Moreover, Lee 
and colleagues retrospectively analyzed 1367 patients 
and found that a high NLR was significantly related to 
unfavorable clinicopathological outcomes and shorter 
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Table 1: Baseline patient characteristics
Variable
Total Low group High group
p value
n = 2032 (%) 1579 (77.7) 453 (22.3)
Age, years (median) 66 66 66 0.007
 IQR 61–70 61–70 62–70
PSA, ng/ml (median) 8.1 7.9 9.3 0.001
 IQR 5.4–13.5 5.3–13.1 5.7–15.2
BMI, kg/m2 (median) 24.1 24.2 23.7 0.004
 IQR 22.3–25.7 22.5–25.7 21.9–25.4
Hypertension 0.748
 No 1118 (55.0) 872 (55.2) 246 (54.3)
 Yes 914 (45.0) 707 (44.8) 207 (45.7)
DM >0.999
 No 1675 (82.4) 1301 (82.4) 374 (82.6)
 Yes 357 (17.6) 278 (17.6) 79 (17.4)
CVD 0.200
 No 1842 (90.6) 1424 (90.2) 418 (92.3)
 Yes 190 (9.4) 155 (9.8) 35 (7.7)
CVA 0.421
 No 1917 (94.3) 1493 (94.6) 424 (93.6)
 Yes 115 (5.7) 86 (5.4) 29 (6.4)
Gleason score >0.999
 <7 621 (30.6) 483 (30.6) 138 (30.5)
 ≥7 1411 (69.4) 1096 (69.4) 315 (69.5)
PSM 0.632
 No 1039 (51.1) 812 (51.4) 227 (50.1)
 Yes 993 (48.9) 767 (48.6) 226 (49.9)
T stage 0.048
 T2 935 (46.0) 708 (44.8) 227 (50.1)
 T3 1097 (54.0) 871 (55.2) 226 (49.9)
LN metastasis 0.351
 No 1920 (94.5) 1496 (94.7) 424 (93.6)
 Yes 112 (5.5) 83 (5.3) 29 (6.4)
(Continued )
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Figure 1: Kaplan-Meier curves for biochemical recurrence (BCR)-free survival in patients with high postoperative 
neutrophil to lymphocyte ratio (NLR) and low NLR.
Variable
Total Low group High group
p value
n = 2032 (%) 1579 (77.7) 453 (22.3)
Preoperative neutrophil, ×103/μl 
(median)
3.52 3.46 3.78 <0.001
 IQR 2.83–4.44 2.79–4.33 2.99–4.73
Preoperative lymphocyte, ×103/μl 
(median)
1.97 2.01 1.82 <0.001
 IQR 1.59–2.42 1.63–2.46 1.49–2.30
Postoperative neutrophil, ×103/μl 
(median)
4.01 3.62 6.92 <0.001
 IQR 3.05–5.31 2.86–4.53 5.13–9.00
Postoperative lymphocyte, ×103/μl 
(median)
1.77 1.93 1.20 <0.001
 IQR 1.36–2.25 1.56–2.37 0.96–1.52
Abbreviations: BMI = body mass index; CI = confidence interval; CVA = cerebral vascular accident; CVD = cardiovascular 
disease; DM = diabetes mellitus; HR = hazard ratio; IQR = interquartile range; LN = lymph node; NLR = neutrophil to 
lymphocyte ratio; PSA = prostate specific antigen; PSM = positive surgical margin.
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Table 2: Univariate and multivariate analyses of factors associated with biochemical recurrence
Variable
Univariate Multivariate
HR (95% CI) p value HR (95% CI) p value
Age 1.024 (1.012–1.035) <0.001 1.012 (1.001–1.024) 0.040
PSA 1.005 (1.004–1.006) <0.001 1.004 (1.003–1.005) <0.001
BMI 0.981 (0.951–1.012) 0.236
Hypertension
 No 1 (Ref)
 Yes 1.055 (0.906–1.229) 0.489
DM
 No 1 (Ref)
 Yes 1.180 (0.974–1.431) 0.091
CVD
 No 1 (Ref)
 Yes 1.221 (0.956–1.560) 0.109
CVA
 No 1 (Ref)
 Yes 1.077 (0.776–1.495) 0.656
Gleason score
 <7 1 (Ref) 1 (Ref)
 ≥7 4.240 (3.342–5.379) <0.001 3.069 (2.400–3.924) <0.001
PSM
 No 1 (Ref) 1 (Ref)
 Yes 2.820 (2.392–3.324) <0.001 1.992 (1.669–2.376) <0.001
T stage
 T2 1 (Ref) 1 (Ref)
 T3 2.546 (2.152–3.013) <0.001 1.469 (1.222–1.765) <0.001
LN metastasis
 No 1 (Ref) 1 (Ref)
 Yes 1.910 (1.449–2.518) <0.001 1.535 (1.163–2.027) 0.002
Delta NLR
 Decrease 1 (Ref)
 Increase 1.162 (0.986–1.369) 0.074
Postoperative NLR
 Low 1 (Ref) 1 (Ref)
 High 1.259 (1.057–1.499) 0.010 1.270 (1.066–1.514) 0.008
Abbreviations: BMI = body mass index; CI = confidence interval; CVA = cerebral vascular accident; CVD = cardiovascular 
disease; DM = diabetes mellitus; HR = hazard ratio; LN = lymph node; NLR = neutrophil to lymphocyte ratio; PSA = 
prostate specific antigen; PSM = positive surgical margin.
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BCR-free survival [17]. Others reported that high NLR 
was associated with higher BCR risk. Our previous study 
found that a high preoperative NLR was associated with 
overall and cancer-specific mortality but not with BCR 
[16]. Similarly, Bahig et al. demonstrated that NLR was not 
associated with BCR after RP for localized PC [26]. Kwon 
et al. determined that BCR after RP was not significantly 
different between the high and low NLR groups [27].
Given the inconsistent BCR results across studies, 
we decided to focus on the prognostic value of NLR in 
the postoperative setting. Our results show that elevated 
postoperative NLR is a useful independent prognostic 
factor for BCR and OS in patients with localized PC. 
Similarly, Kang et al. reported that postoperative NLR 
was a significant predictive factor for survival outcomes 
in patients with urothelial carcinoma of the bladder 
undergoing radical cystectomy [12]. Li et al. suggested 
that the postoperative NLR combined with the platelet-
to-lymphocyte ratio predicted outcomes of hepatitis B 
virus-related hepatocellular carcinoma patients after 
liver resection [19]. Shibutani et al. reported that the 
postoperative NLR is an independent prognostic factor in 
patients with colorectal cancer who underwent potentially 
curative surgery [28].
NLR reflects the balance between innate (neutrophil-
mediated) and adaptive (lymphocyte-mediated) immune 
responses [11]. Thus, high and low NLR values after 
RP suggest pro- and anti-tumor inflammatory responses, 
respectively. Postoperative NLR could therefore reflect 
residual host immune activity after RP. In addition, 
surgical stress is a systemic response to surgical injury 
and is characterized by sympathetic nervous system 
activation, endocrine responses, and immunological 
and hematological changes [29]. Such stress could shift 
the host systemic inflammatory state in favor of tumor 
recurrence and growth after RP [19]. In this regard, 
postoperative NLR can reflect how a patient’s systemic 
immune activity has changed after surgery. Both the 
pre- and postoperative NLR values should be considered 
when predicting the prognosis of patients with PC who 
underwent RP.
There are several strengths to our study. First, to 
our best knowledge, this is the first investigation of the 
prognostic significance of postoperative NLR in patients 
with PC who underwent RP. Second, our cohort included 
a large number of patients with sufficiently long-term 
follow-up durations, which allowed us to show that a 
high postoperative NLR was significantly associated 
Figure 2: Kaplan-Meier curves for overall survival in patients with high postoperative neutrophil to lymphocyte ratio 
(NLR) and low NLR.
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Table 3: Univariate and multivariate analyses of factors associated with overall survival
Variable
Univariate Multivariate
HR (95% CI) p value HR (95% CI) p value
Age 1.085 (1.057–1.113) <0.001 1.079 (1.051–1.108) <0.001
PSA 1.003 (1.000–1.006) 0.077
BMI 0.960 (0.897–1.029) 0.249
Hypertension
 No 1 (Ref)
 Yes 1.204 (0.883–1.642) 0.240
DM
 No 1 (Ref)
 Yes 1.606 (1.126–2.290) 0.009 1.476 (1.032-2.110) 0.033
CVD
 No 1 (Ref)
 Yes 1.553 (0.981–2.458) 0.060
CVA
 No 1 (Ref)
 Yes 1.729 (0.999–2.992) 0.050
Gleason score
 <7 1 (Ref) 1 (Ref)
 ≥7 1.949 (1.316–2.885) 0.001 1.643 (1.106–2.440) 0.014
PSM
 No 1 (Ref) 1 (Ref)
 Yes 1.478 (1.080–2.024) 0.015 1.214 (0.875–1.684) 0.245
T stage
 T2 1 (Ref) 1 (Ref)
 T3 1.413 (1.028–1.942) 0.033 1.019 (0.706–1.470) 0.922
LN metastasis
 No 1 (Ref) 1 (Ref)
 Yes 2.498 (1.564–3.992) <0.001 2.336 (1.457–3.744) <0.001
Delta NLR
 Decrease 1 (Ref)
 Increase 0.913 (0.650–1.283) 0.600
Postoperative NLR
 Low 1 (Ref) 1 (Ref)
 High 1.548 (1.109–2.160) 0.010 1.437 (1.029–2.007) 0.033
Abbreviations: BMI = body mass index; CI = confidence interval; CVA = cerebral vascular accident; CVD = cardiovascular 
disease; DM = diabetes mellitus; HR = hazard ratio; LN = lymph node; NLR = neutrophil to lymphocyte ratio; PSA = 
prostate specific antigen; PSM = positive surgical margin.
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with both short- and also long-term survival. Lastly, our 
postoperative follow-up protocol was homogeneous. No 
patient received adjuvant androgen deprivation therapy or 
radiotherapy until BCR, which allowed us to observe the 
natural history of BCR after RP.
Our analysis also has several limitations. First, this 
was a retrospective review of data from patients treated at 
a single institution, so our results may not be generalizable. 
Second, after cancer recurrence, patients in our study were 
treated based on their clinician’s practices. Third, other 
systemic inflammation markers such as C-reactive protein 
and albumin were not routinely available and could not be 
included in our analysis. Further prospective, multicenter 
studies are needed to confirm our results.
In conclusion, our study demonstrates that 
postoperative NLR is an independent prognostic factor 
for BCR and OS in patients who underwent RP for PC. As 
our findings suggest, we believe NLR can be a valuable 
tool for not only stratifying high-risk patients, but also for 
facilitating the decision-making of postoperative therapy 
for patients with prostate cancer.
MATERIALS AND METHODS
Patients
After obtaining approval from the Institutional 
Review Board of the Severance Hospital, we 
retrospectively reviewed medical records of 2,302 
patients, with clinically localized or locally advanced 
PC, who underwent RP at our institution between 
January 2000 and December 2010. Among these 
patients, we only considered those who had perioperative 
leukocyte parameters from peripheral blood including 
neutrophil, lymphocyte, and total leukocyte counts. 
We excluded patients with a history of double primary 
cancers, autoimmune or systemic inflammatory diseases 
that may influence NLR values, as well as those with 
suspected bacterial or viral infection by laboratory 
results. We also excluded patients under neoadjuvant 
or adjuvant therapy, and those with incomplete medical 
records.
Patient characteristics
Clinical characteristics including age, PSA at the 
time of biopsy, BMI, pathological Gleason score, PSM, 
pathological T stage, and LN metastasis were obtained 
through a review of medical records at our institution. TNM 
stage was determined according to the 7th edition of the 
American Joint Committee on Cancer TNM staging system 
[30]. Pathological analysis of RP specimens was performed 
by a single experienced uropathologist. We included 
the data on metabolic comorbidities (hypertension, 
DM, CVD and a prior CVA) associated with systemic 
inflammation, which are important predictors of long-term 
survival outcomes in patients with prostate cancer. For 
perioperative leukocyte parameters counts, preoperative 
values were obtained from routine laboratory tests within 
one month before RP, while postoperative counts were 
taken during the recovery period of two to three months 
after RP. Delta NLR was defined as postoperative NLR 
minus preoperative NLR [19].
Follow-up
Postoperative PSA follow-up was performed 
monthly for the first 6 months, every 3 months for the 
second year, and semiannually thereafter. BCR was defined 
as any two consecutive increases in serum PSA ≥0.2 ng/ml 
following RP [31]. BCR-free survival was defined as the 
time from RP to BCR. Mortality data were obtained from 
medical records in our institution’s Cancer Registry Center 
database [32]. The follow-up period was calculated from 
the time of RP to the date of the last known contact with 
the patient or the date of death. OS was defined as the time 
from RP to the date of death by any cause.
Statistical analysis
The NLR was calculated by dividing the 
neutrophil count by the lymphocyte count. To determine 
the optimal cut-off value of NLR, we performed survival 
analysis with the Kaplan–Meier method with a log-
rank test based on the NLR quartiles (1st quartile, NLR 
≤1.6; 2nd quartile, 1.6 < NLR ≤ 2.3; 3rd quartile, 2.3 
< NLR ≤ 3.5; 4th quartile, NLR >3.5). There was a 
significant difference in BCR-free survival for the top 
25th percentile (NLR cut-off of 3.5) when the cohort 
was dichotomized by quartiles. We compared clinical 
and pathological characteristics between groups using 
Mann–Whitney U tests for continuous data and χ2 tests 
for dichotomous variables. We used the Kaplan-Meier 
method with log-rank tests to estimate and compare 
oncologic outcomes according to NLR group. Cox 
proportional hazard models were used to investigate 
associations between variables and the risks of oncologic 
outcomes. Significant variables from univariate analysis 
were included in the multivariate analysis. All analyses 
were conducted using SPSS 18.0 software (SPSS, Inc., 
Chicago, IL, USA). Comparisons with p < 0.05 were 
considered statistically significant.
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